The Raynaud's disease treatment market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.49 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. This growth during the historic period is attributed to a rise in awareness of autoimmune diseases, enhanced diagnostic techniques, broader application of calcium channel blockers, a growing incidence of connective tissue disorders, and an aging population.
The Raynaud's disease treatment market size is expected to see strong growth in the next few years. It will grow to $1.98 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. Contributing factors to this projected growth include the increasing adoption of telehealth for vascular care, the development of personalized treatment approaches, ongoing studies into endothelial dysfunction, a higher prevalence driven by extreme weather conditions, and improvements in global healthcare systems. Notable trends anticipated during the forecast period include the use of AI for early detection and disease tracking, innovations in digital thermal diagnostic tools, progress in targeted biological therapies, emerging advancements in gene editing and cell therapy, as well as the wider implementation of digital health and telemedicine solutions.
The growing prevalence of autoimmune diseases is anticipated to drive the expansion of the Raynaud’s disease treatment market. Autoimmune diseases occur when the immune system mistakenly attacks the body’s healthy tissues, leading to inflammation and tissue damage. This rise in autoimmune disorders is attributed to factors such as urbanized and sanitized living conditions that limit immune system training, as well as modern lifestyle elements like poor diet, stress, and environmental pollutants. Treatments for Raynaud’s disease aid in managing autoimmune symptoms by improving symptom control, reducing tissue damage, and preventing complications caused by restricted blood flow. For example, in June 2024, a report from the Australian Institute of Health and Welfare revealed that in 2021-22 there were 10,000 hospitalizations for rheumatoid arthritis in Australia, a 25% increase from 8,000 the previous year, equivalent to 39 hospitalizations per 100,000 population. As a result, the increasing incidence of autoimmune conditions is fueling the growth of the Raynaud’s disease treatment market.
Increasing healthcare expenditure is also expected to contribute to the growth of the Raynaud’s disease treatment market. Healthcare expenditure refers to the total financial resources spent on medical services and health-related needs over a specific time period. As the global population ages, the demand for healthcare services, long-term care, and treatments for age-related conditions rises, leading to greater overall health spending. Increased healthcare investment enhances Raynaud’s disease treatment by improving access to medications, diagnostics, and specialized care, while also supporting research and public awareness efforts. For instance, in April 2025, the American Medical Association reported that in 2023, U.S. health spending rose by 7.5% to reach $4.9 trillion, or $14,570 per person, a notable increase from the 4.6% growth recorded in 2022. This surge in spending supports the development and accessibility of treatments, thereby driving market growth.
Leading companies in the Raynaud’s disease treatment market are concentrating on developing innovative therapeutic solutions, particularly oral calcium channel blockers that enhance blood flow by relaxing and dilating blood vessels, helping to reduce the frequency and severity of vasospastic attacks. Oral calcium channel blockers are medications taken by mouth that inhibit calcium entry into muscle cells in the heart and blood vessels, promoting vasodilation. For instance, in June 2023, Aisa Pharma Inc., a U.S.-based clinical-stage biopharmaceutical firm, launched the second part of its Phase 2b RECONNOITER trial to evaluate Profervia (cilnidipine), an oral calcium channel blocker, for treating Raynaud’s phenomenon in individuals with systemic sclerosis (SSc). The trial follows encouraging results from the first phase, where Profervia demonstrated a more significant reduction in attack frequency and disease severity compared to other calcium channel blockers, along with a favorable safety and tolerability profile. The ongoing trial with a 20 mg dose seeks to meet the urgent need for effective Raynaud’s treatments in SSc, which currently lacks approved therapies.
Major players in the raynauds disease treatment market are Pfizer Inc., Johnson & Johnson, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., CSL Vifor, Orion Corporation, Apricus Biosciences Inc., Vicore Pharma Holding AB, MediQuest Therapeutics Inc., Gesynta Pharma AB, Aisa Pharma Inc., and Concert Pharmaceuticals Inc.
North America was the largest region in the raynauds disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in raynauds disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the raynauds disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Raynaud's disease treatment involves both medical and lifestyle approaches designed to lessen the frequency and severity of blood vessel spasms in the fingers and toes caused by cold or emotional stress. This includes the use of medications such as calcium channel blockers to enhance blood circulation, as well as preventive actions like staying warm and managing stress effectively.
There are several main types of treatments available for Raynaud's disease, including medications, thermal therapies, surgical interventions, and alternative treatments. Medications typically consist of calcium channel blockers and vasodilators that enhance blood flow and alleviate Raynaud’s symptoms. These drug types include calcium channel blockers, vasodilators, and antiplatelet agents, which may be administered via oral, topical, injectable, or intravenous routes. Treatment settings include hospitals, specialty clinics, homecare environments, and pharmacies.
The Raynaud's disease treatment market research report is one of a series of new reports that provides Raynaud's disease treatment market statistics, including Raynaud's disease treatment industry global market size, regional shares, competitors with a Raynaud's disease treatment market share, detailed Raynaud's disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the Raynaud's disease treatment industry. This Raynaud's disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The raynauds disease treatment market consists of revenue earned by entities by providing services such as pharmacological management, thermal therapy services, surgical consultation, and behavioral therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The raynauds disease treatment market also includes sales of vasodilators, prostaglandins, hand warmers, thermal gloves, heated socks, and paraffin wax baths. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The Raynaud's disease treatment market size is expected to see strong growth in the next few years. It will grow to $1.98 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. Contributing factors to this projected growth include the increasing adoption of telehealth for vascular care, the development of personalized treatment approaches, ongoing studies into endothelial dysfunction, a higher prevalence driven by extreme weather conditions, and improvements in global healthcare systems. Notable trends anticipated during the forecast period include the use of AI for early detection and disease tracking, innovations in digital thermal diagnostic tools, progress in targeted biological therapies, emerging advancements in gene editing and cell therapy, as well as the wider implementation of digital health and telemedicine solutions.
The growing prevalence of autoimmune diseases is anticipated to drive the expansion of the Raynaud’s disease treatment market. Autoimmune diseases occur when the immune system mistakenly attacks the body’s healthy tissues, leading to inflammation and tissue damage. This rise in autoimmune disorders is attributed to factors such as urbanized and sanitized living conditions that limit immune system training, as well as modern lifestyle elements like poor diet, stress, and environmental pollutants. Treatments for Raynaud’s disease aid in managing autoimmune symptoms by improving symptom control, reducing tissue damage, and preventing complications caused by restricted blood flow. For example, in June 2024, a report from the Australian Institute of Health and Welfare revealed that in 2021-22 there were 10,000 hospitalizations for rheumatoid arthritis in Australia, a 25% increase from 8,000 the previous year, equivalent to 39 hospitalizations per 100,000 population. As a result, the increasing incidence of autoimmune conditions is fueling the growth of the Raynaud’s disease treatment market.
Increasing healthcare expenditure is also expected to contribute to the growth of the Raynaud’s disease treatment market. Healthcare expenditure refers to the total financial resources spent on medical services and health-related needs over a specific time period. As the global population ages, the demand for healthcare services, long-term care, and treatments for age-related conditions rises, leading to greater overall health spending. Increased healthcare investment enhances Raynaud’s disease treatment by improving access to medications, diagnostics, and specialized care, while also supporting research and public awareness efforts. For instance, in April 2025, the American Medical Association reported that in 2023, U.S. health spending rose by 7.5% to reach $4.9 trillion, or $14,570 per person, a notable increase from the 4.6% growth recorded in 2022. This surge in spending supports the development and accessibility of treatments, thereby driving market growth.
Leading companies in the Raynaud’s disease treatment market are concentrating on developing innovative therapeutic solutions, particularly oral calcium channel blockers that enhance blood flow by relaxing and dilating blood vessels, helping to reduce the frequency and severity of vasospastic attacks. Oral calcium channel blockers are medications taken by mouth that inhibit calcium entry into muscle cells in the heart and blood vessels, promoting vasodilation. For instance, in June 2023, Aisa Pharma Inc., a U.S.-based clinical-stage biopharmaceutical firm, launched the second part of its Phase 2b RECONNOITER trial to evaluate Profervia (cilnidipine), an oral calcium channel blocker, for treating Raynaud’s phenomenon in individuals with systemic sclerosis (SSc). The trial follows encouraging results from the first phase, where Profervia demonstrated a more significant reduction in attack frequency and disease severity compared to other calcium channel blockers, along with a favorable safety and tolerability profile. The ongoing trial with a 20 mg dose seeks to meet the urgent need for effective Raynaud’s treatments in SSc, which currently lacks approved therapies.
Major players in the raynauds disease treatment market are Pfizer Inc., Johnson & Johnson, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., CSL Vifor, Orion Corporation, Apricus Biosciences Inc., Vicore Pharma Holding AB, MediQuest Therapeutics Inc., Gesynta Pharma AB, Aisa Pharma Inc., and Concert Pharmaceuticals Inc.
North America was the largest region in the raynauds disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in raynauds disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the raynauds disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Raynaud's disease treatment involves both medical and lifestyle approaches designed to lessen the frequency and severity of blood vessel spasms in the fingers and toes caused by cold or emotional stress. This includes the use of medications such as calcium channel blockers to enhance blood circulation, as well as preventive actions like staying warm and managing stress effectively.
There are several main types of treatments available for Raynaud's disease, including medications, thermal therapies, surgical interventions, and alternative treatments. Medications typically consist of calcium channel blockers and vasodilators that enhance blood flow and alleviate Raynaud’s symptoms. These drug types include calcium channel blockers, vasodilators, and antiplatelet agents, which may be administered via oral, topical, injectable, or intravenous routes. Treatment settings include hospitals, specialty clinics, homecare environments, and pharmacies.
The Raynaud's disease treatment market research report is one of a series of new reports that provides Raynaud's disease treatment market statistics, including Raynaud's disease treatment industry global market size, regional shares, competitors with a Raynaud's disease treatment market share, detailed Raynaud's disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the Raynaud's disease treatment industry. This Raynaud's disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The raynauds disease treatment market consists of revenue earned by entities by providing services such as pharmacological management, thermal therapy services, surgical consultation, and behavioral therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The raynauds disease treatment market also includes sales of vasodilators, prostaglandins, hand warmers, thermal gloves, heated socks, and paraffin wax baths. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Raynauds Disease Treatment Market Characteristics3. Raynauds Disease Treatment Market Trends And Strategies4. Raynauds Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Raynauds Disease Treatment Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Raynauds Disease Treatment Market34. Recent Developments In The Raynauds Disease Treatment Market
5. Global Raynauds Disease Treatment Growth Analysis And Strategic Analysis Framework
6. Raynauds Disease Treatment Market Segmentation
7. Raynauds Disease Treatment Market Regional And Country Analysis
8. Asia-Pacific Raynauds Disease Treatment Market
9. China Raynauds Disease Treatment Market
10. India Raynauds Disease Treatment Market
11. Japan Raynauds Disease Treatment Market
12. Australia Raynauds Disease Treatment Market
13. Indonesia Raynauds Disease Treatment Market
14. South Korea Raynauds Disease Treatment Market
15. Western Europe Raynauds Disease Treatment Market
16. UK Raynauds Disease Treatment Market
17. Germany Raynauds Disease Treatment Market
18. France Raynauds Disease Treatment Market
19. Italy Raynauds Disease Treatment Market
20. Spain Raynauds Disease Treatment Market
21. Eastern Europe Raynauds Disease Treatment Market
22. Russia Raynauds Disease Treatment Market
23. North America Raynauds Disease Treatment Market
24. USA Raynauds Disease Treatment Market
25. Canada Raynauds Disease Treatment Market
26. South America Raynauds Disease Treatment Market
27. Brazil Raynauds Disease Treatment Market
28. Middle East Raynauds Disease Treatment Market
29. Africa Raynauds Disease Treatment Market
30. Raynauds Disease Treatment Market Competitive Landscape And Company Profiles
31. Raynauds Disease Treatment Market Other Major And Innovative Companies
35. Raynauds Disease Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Raynauds Disease Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on raynauds disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for raynauds disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The raynauds disease treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment Type: Medication; Thermal Therapies; Surgical Procedures; Alteative Therapies2) By Drug Class: Calcium Channel Blockers; Vasodilators; Antiplatelet Agents
3) By Route of Administration: Oral; Topical; Injectable; Intravenous
4) By End-User: Hospitals; Specialty Clinics; Homecare Settings; Pharmacies
Subsegments:
1) By Medication: Calcium Channel Blockers; Alpha Blockers; Vasodilators; Topical Nitrates; Selective Serotonin Reuptake Inhibitors (SSRIs); Phosphodiesterase Inhibitors; Angiotensin Receptor Blockers (ARBs)2) By Thermal Therapies: Hand Warmers; Thermal Gloves; Heated Pads; Biofeedback-Controlled Thermal Devices
3) By Surgical Procedures: Sympathectomy; Nerve Decompression Surgery; Vascular Surgery
4) By Alternative Therapies: Acupuncture; Biofeedback Therapy; Herbal Remedies; Nutritional Supplements; Stress Management Techniques
Key Companies Profiled: Pfizer Inc.; Johnson & Johnson; Bayer AG; Novartis AG; Sanofi SA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson
- Bayer AG
- Novartis AG
- Sanofi SA
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Merck & Co. Inc.
- Teva Pharmaceutical Industries Ltd.
- CSL Vifor
- Orion Corporation
- Apricus Biosciences Inc.
- Vicore Pharma Holding AB
- MediQuest Therapeutics Inc.
- Gesynta Pharma AB
- Aisa Pharma Inc.
- Concert Pharmaceuticals Inc.
